Screening blood donors by nucleic acid amplification technology in Turkey

Basit Öğe Kaydı
dc.contributor.authorOzdemir, Mehmet
dc.contributor.authorTuzuner, Ugur
dc.contributor.authorFeyzioglu, Bahadir
dc.contributor.authorBaykan, Mahmut
dc.contributor.authorBaysal, Bulent
dc.date.accessioned2024-02-23T14:48:57Z
dc.date.available2024-02-23T14:48:57Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractVolunteer blood donors are screened for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infection by various immunoassay methods in Turkey. The risk of enzyme immunoassay (EIA) negative and positive nucleic acid amplification technology (NAT) samples is not clearly understood yet. The purpose of this study is to screen for such donors in Turkey by a commercially available multiplex NAT test. All donors were screened by EIA and then NAT was performed on pools of six blood sera. When NAT reactive pools were determined they resolved to test the single donation samples. Single donor positive NAT sera were discriminated by polymerase chain reaction (PCR)-based diagnostic assay (COBAS AmpliScreen, Roche, USA). Incompatible sample results with EIA and NAT were searched with additional serologic and confirmatory tests. A total of 3000 donors were screened and detected seronegative, 9 HBV NAT cases (0.3%) and 1 HCV (0.03%) and 1 HIV NAT case (0.03%) were detected positively. Follow-up these donors were showed that the HCV yield case was a window period and all HBV NAT yield cases were occult carriers. The use of NAT will detect occult HBV and reduce window period in HCV. The yield rate, especially in occult HBV, was higher than that in non-endemic countries like Europian countries. Therefore, for routine donor screening by NAT will be provided safer blood transfusion in Turkey cost-effectively.en_US
dc.identifier.endpage3821en_US
dc.identifier.issn1936-2625
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85016947977en_US
dc.identifier.startpage3816en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/17921
dc.identifier.volume10en_US
dc.identifier.wosWOS:000399083300159en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherE-Century Publishing Corpen_US
dc.relation.ispartofInternational Journal Of Clinical And Experimental Pathologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBlood Donoren_US
dc.subjectHcven_US
dc.subjectHbven_US
dc.subjectHiven_US
dc.subjectNaten_US
dc.titleScreening blood donors by nucleic acid amplification technology in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu